Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
When we sleep, our brain is filled with spontaneous neural activity. What is it doing?
Daniel Levenstein explains how internally generated brain activity during sleep shapes our cognition, and why NeuroAI is such a powerful approach to understanding the brain.
When we sleep, our brain is filled with spontaneous neural activity. What is it doing?
Daniel Levenstein explains how internally generated brain activity during sleep shapes our cognition, and why NeuroAI is such a powerful approach to understanding the brain.
Unconfounding genetic and environmental factors, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 31 August.
Unconfounding genetic and environmental factors, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 31 August.
Amid funding uncertainty, neuroscientists report a mix of cynicism, persistence
Two years into one of the most tumultuous tenures in U.S. federal funding, researchers outline how they are coping with ongoing changes and reflect on the impact these changes are having on the system more broadly.
Amid funding uncertainty, neuroscientists report a mix of cynicism, persistence
Two years into one of the most tumultuous tenures in U.S. federal funding, researchers outline how they are coping with ongoing changes and reflect on the impact these changes are having on the system more broadly.